A groundbreaking pediatric cancer drug trial co-led by a Seattle Children’s physician-researcher received the prestigious David Sackett Trial of the Year from the Society for Clinical Trials on May 20 at the organization’s annual meeting in Vancouver, British Columbia.
The Children’s Oncology Group AALL1731 clinical trial, which concluded last year, showed adding the drug blinatumomab to a chemotherapy regimen for children with B-cell acute lymphoblastic lymphoma (B-ALL) decreased risk of relapse by about two-thirds. These findings represent the biggest breakthrough in childhood cancer treatment in decades.
